US$ 22.02
glp 1 dual agonist Efficacy of glucagon-like peptide-1 and estrogen in pancreatic islets protection and pre-clinical models of insulin-deficient diabetes The Sustained Effects of a
Description
Gerti Tashko, MD, is an endocrinologist in Montgomery County, Maryland

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice

Liu Y, Yang F, Feng L, Yang L
A recent large population-based cohort study using UK primary care data evaluated the risk of suicidality among patients with type 2 diabetes initiating GLP-1 RAs (n = 36,371) compared to DPP-4 inhibitors (n = 232,511) or sodium-glucose cotransporter-2 (SGLT-2) inhibitors (n = 104,386)

Care 8 , e001600 (2020)

Neuroprotective effects of glucagon-like peptide-1 (GLP-1) analogues in epilepsy and associated comorbidities
